- For Q3, co posted upside results for EPS and for revs, which rose +42% yr/yr to $75.6 mln. Testing services volume grew +86% yr/yr. Raised its guidance for FY21 revs to $290-293 mln, in-line with estimates. Falls to 52-week lows.
** charts after earnings **
CareDx beats by $0.05, beats on revs; raises FY21 revs in-line
- Reports Q3 (Sep) earnings of $0.07 per share, excluding non-recurring items, $0.05 better than the S&P Capital IQ Consensus of $0.02; revenues rose 41.6% year/year to $75.6 mln vs the $74.11 mln S&P Capital IQ Consensus.
- Co issues raised guidance for FY21, sees FY21 revs of $290-293 mln from $280-290 mln vs. $290.48 mln S&P Capital IQ Consensus.
No comments:
Post a Comment